In a functionally screened cohort, there was an 85% likelihood of being free of local treatment failure at 3 years, with outcomes favoring nodules smaller than 3 cm.
Researchers urge caution in interpreting joint replacement predictors, noting that surgery reflects access and decision-making as well as disease biology.
Teriparatide followed by zoledronic acid increased bone mineral density but did not reduce fracture risk compared with standard care in adults with osteogenesis imperfecta.